(SEATTLE)Drug developer Dendreon Corp. on Friday said expenses connected to its April stock offering pushed its third-quarter loss up 39 percent. The company's loss expanded to $26.8 millio...READ MORE
(NEW YORK)Shares of Dendreon Corp. tumbled Tuesday as investors backed off the prior day's big gains on data showing that a developing prostate cancer vaccine could meet its goal in a late-s...READ MORE
Among the stock activity stories for Tuesday, Oct. 7, from AP Financial News: NEW YORK (AP)--Shares of drugstore operator Rite Aid sank to an all-time low Tuesday, but analysts see...READ MORE
(SEATTLE)Dendreon Corp. said Monday that its prostate cancer vaccine candidate Provenge may be on target to meet its main goal in a late-stage clinical trial. The biotechnology company said...READ MORE
(NEW YORK)Shares of Cell Genesys Inc. crashed to an all-time low Wednesday after the company stopped a clinical trial of its prostate cancer vaccine GVAX because of patient deaths.READ MORE